23/08/2017
PUNE: Eisai
Pharmaceuticals India Pvt. Ltd, a leading Japanese pharmaceutical company announced
the launch of Fycompa (perampanel), a new anti-epileptic drug. Approved in more
than 55 countries worldwide, Fycompa is indicated as an adjunctive therapy
for the treatment of partial-onset seizures (POS) with or without secondarily
generalized seizures in patients with epilepsy aged 12 and older.
Fycompa is first in class in-house developed anti-epileptic
drug, available in tablet form as a once-daily oral dose. “Nearly 12 million
patients in India suffer from epilepsy and 95% of these patients do not receive
adequate treatment. Abiding by our core philosophy of human health care we
strive to change this by developing a drug that can significantly improve the
quality of life of epileptic patients and give them hope to live a seizure
free-life,” said Sanjit Singh Lamba, MD, Eisai Pharmaceuticals India.”
Adding to this Dr. Manoj Malhotra, Head of Medical Affairs,
Americas Region, Global Head of Epilepsy Medical Affairs, Neurology Business
Group, Eisai Inc. said “With the launch of many anti-epileptic drugs in
the last decade we have seen a significant improvement in seizure freedom rate.
However, almost 30-40% of the seizures remain poorly controlled leading to low
compliance. Fycompa will help to address these key therapeutic challenges and
improve patient outcomes”.
Commenting on the low awareness on epilepsy, Mr. Saumil Mody, VP,
Commercial Operations, Eisai India Ltd. said “Treatment outcomes for
epilepsy are very low because we are dealing with very challenging
circumstances, a majority of epilepsy cases go undiagnosed because of numerous
factors like the social stigma associated with the disease, lack of awareness
of the symptoms particularly in rural India. Our aim is to address these
challenges and enable epileptic patients and their families to live a
seizure-free life.”
Epilepsy is a condition that affects the brain and causes repeated seizures. Approximately 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.
0 comments:
Post a Comment